Key Market Indicator:
Welcome our new Research Provider
In the Research & Ratings section, you can access assessments from renowned analyst firms that specialize in the due diligence and valuation of companies that are generally listed on the stock exchange. Starting from the research reports, you can access further research tools and information with just a few mouse clicks, which offer you additional options for obtaining and assessing information.
Wed, 09.02.2022
MagForce AG
In the past fiscal year 2021, MagForce AG made progress in both business
segments. Of particular note here is the approval granted by the FDA for
the start of Stage 2b for the treatment of prostate cancer patients. This
means that the pivotal study could be concluded as early as summer 2022. In
parallel, the treatment capacities for the indication [ … ]
Wed, 02.02.2022
Saturn Oil & Gas Inc.
Oxbow facilities
We had the chance to visit the newly acquired Oxbow Asset in September
2021. The site visit included a complete tour and presentation of new
management as well as a trip to production assets, pads, facilities and an
introduction to many employees and contractual companies. The assets
visited were located in a fairly concentrated [ … ]
Wed, 02.02.2022
Cogia AG
Preliminary results significantly above forecast, price target confirmed
On January 21, 2022, Cogia AG published its preliminary figures for the
2021 financial year and the figures presented exceed the GBC analysts'
forecasts. A total output of EUR 1.7 million was achieved in the group,
which corresponds to almost a threefold increase (previous [ … ]
Fri, 28.01.2022
HAEMATO AG
PCR PoC-Device added to the product portfolio; revenue and earnings
forecasts unchanged, upside potential anticipated from new products, price
target and BUY rating confirmed
In our last management interview (http://www.more-ir.de/d/23165.pdf) on the
current developments of HAEMATO AG, the CEO Patrick Brenske had announced
the addition of a mobi [ … ]
Mon, 24.01.2022
Defence Therapeutics Inc.
GBC Research Watchlist: Defence Therapeutics
Defence Therapeutics is led by Sebastien Plouffe. Mr. Plouffe has been a
successful Investment Advisor and CEO notably in the resource sector,
leading several junior companies to profitable exits. Mr. Plouffe is
supported by Dr. Moutih Rafei, VP R&D and Dr. Simon Beaudoin CTSO. Dr.
Rafei is a worl [ … ]
Wed, 19.01.2022
The NAGA Group AG
Strong revenue and earnings growth in 2021; guidance for 2022 significantly
above our expectations; estimates and share price target raised
According to preliminary figures for the past financial year 2021, The NAGA
Group AG (short to: NAGA) achieved significant revenue growth as expected.
Compared to the previous year, consolidated sales more t [ … ]
Mon, 27.12.2021
Cryptology Asset Group PLC
Cryptology is a leading European holding company for crypto assets and
blockchain companies.
Cryptology Asset Group is a publicly traded investment company focused on
crypto-assets and blockchain-based business models. For this purpose,
Cryptology has a broad network of experts, including Christian Angermayer
and Mike Novogratz, two of the most [ … ]
Tue, 21.12.2021
Saturn Oil & Gas Inc.
Record quarter production 6,970 boe/d
Record quarter Free Cash Flow $9.5M CAD
Record production. The company has produced 6,970 boe/d during Q3-2021.
This represents an increase of 270% over their Q2 results and 1297% over Q3
2020.
Record Free Cash Flow. The company Q3 EBITDA resulted in $17.2M CAD. The
company posted a $9.5M CAD positive fr [ … ]
Tue, 21.12.2021
Cogia AG
Dynamic growth with patented semantic solutions in the area of 'Big Data
Analytics'
Cogia AG is a full-service provider of AI-based, patented, semantic
solutions and services in the field of 'Big Data Analytics', with a focus
on customer experience, monitoring and engagement. Cogia's goal is to
support its customers, whether companies, associati [ … ]
Mon, 13.12.2021
Aspermont Limited
Preliminary FY2021 shows positive Net Profit After Tax
FY2021 preliminary report shows continued growth
As per their preliminary numbers, the company has delivered on all their
guidance:
- Overall growth
- Subscriptions growth rate to go back to pre-Covid-19 levels
- Growth in audience
- High growth in new products
- Continue [ … ]
